Stockscreener 앱 받기
38.82
4.85%
-1.98
시간 외 거래:
38.82
전일 마감가:
$40.80
열려 있는:
$40.73
하루 거래량:
648.05K
Relative Volume:
1.18
시가총액:
$1.92B
수익:
-
순이익/손실:
$-105.43M
주가수익비율:
-16.75
EPS:
-2.3183
순현금흐름:
$-88.42M
1주 성능:
+21.35%
1개월 성능:
+19.74%
6개월 성능:
+149.65%
1년 성능:
+233.79%
1일 변동 폭
$37.76
$40.73
1주일 범위
$32.30
$42.88
52주 변동 폭
$5.485
$42.88
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
38.82 | 2.02B | 0 | -105.43M | -88.42M | -2.3183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Piper Sandler | Overweight |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - MSN
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World
Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st
Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oruka Therapeutics, Inc. $ORKA is Fairmount Funds Management LLC's 7th Largest Position - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen - MarketBeat
Commodore Capital LP Has $33.71 Million Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com India
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Barclays Raises Price Target for ORKA to $50, Maintains Overweig - GuruFocus
ORKA’s Recent Moves Signal Strategic Realignment Amid Market Shifts - timothysykes.com
Barclays Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $72.00 - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week High on Strong Earnings - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
BTIG reiterates Buy on Oruka Therapeutics stock, $73 target - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Receives "Outperform" Rating from Wedbush - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from Guggenheim - MarketBeat
BTIG Maintains Buy on Oruka Therapeutics (ORKA) March 13, 2026 - Meyka
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - Sahm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Oruka Therapeutics (NASDAQ:ORKA) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Oruka psoriasis drug targets twice-yearly dosing in Phase 2 trials - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 7.8%Time to Sell? - MarketBeat
Should Oruka’s Once-Yearly ORKA-001 Psoriasis Dosing Ambition Require Action From Oruka Therapeutics (ORKA) Investors? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Piper Sandler initiates coverage of Oruka Therapeutics (ORKA) with overweight recommendation - MSN
Published on: 2026-03-08 05:39:15 - baoquankhu1.vn
Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 17.2% in February - MarketBeat
Is Oruka Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Rallies & Smart Allocation Stock Reports - mfd.ru
Oruka Therapeutics COO Sandler sells $167,821 in shares - Investing.com
Oruka Therapeutics Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - Defense World
Oruka Therapeutics Inc (ORKA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):